Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. The NODE-301 Trial.
Principal Investigator
Matthew BennettOverview
Study Start/End
Oct 11, 2018 to Nov 1, 2019Locations
Diamond Health Care CentreName/Title
Matthew Wei, Research CoordinatorPhone
604-875-5104Email Address
matthew.wei@vch.caPurpose of Study
The purpose of this study is to determine whether etripamil nasal spray (NS) 70 mg is superior to placebo at terminating episodes of Paroxysmal Supraventricular Tachycardia (PSVT) in an outpatient setting.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.